This study evaluates the preclinical efficacy and safety of CB307, a trispecific Humabody VH therapeutic targeting PSMA on tumor cells, CD137 on T cells, and HSA for half-life extension, aiming to induce localized T-cell activation in PSMA-expressing tumors.
CB307 induces PSMA-dependent CD137 activation, enhances T-cell proliferation and cytokine production, inhibits tumor growth in PSMA-expressing tumor models, shows synergistic effects with PD-1/PD-L1 inhibitors, and exhibits a favorable safety profile in preclinical studies.
Double-humanized HSA-FcRn transgenic mouse model developed by genOway, expressing human serum albumin (HSA) and human neonatal Fc receptor (hFcRn) to study the pharmacokinetics and therapeutic effects of CB307.
Prostate cancer, Immunotherapy, T-cell activation, PSMA-targeted therapy, CD137 agonist, Pharmacokinetics
Double-humanized HSA-FcRn transgenic mouse, Human FcRn and HSA expression, PSMA/CD137/HSA targeting, In vivo tumor models, T-cell activation assays, Pharmacokinetic analysis
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Comprehensive dataset package
Generated with biopharma partners and in-house
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Breeding facilities in US and Europe
Certified health status from professional breeders
